SCIENTECH (02291) surged more than 35% in afternoon trading. At the time of writing, the stock was up 30.63% to HK$18.55, with a turnover of HK$66.72 million. A research report noted that the volume of TAVR procedures in mainland China has been rising continuously from 2010 to 2025, exceeding 18,000 cases in 2025, a year-on-year increase of 8.1%. The proportion of balloon-expandable valve implants has shown a yearly upward trend, accounting for 7.50% of TAVR patients in 2024 and 13% in 2025. Meanwhile, long-term follow-up data for both self-expanding and balloon-expandable valves are set to be released by the end of 2025 and early 2026, respectively, revealing differences in durability. Public information indicates that among the several subsidiaries of Lepu Medical, SCIENTECH focuses on heart valves and occluders, while Lepu Biotechnology specializes in innovative oncology drugs. SCIENTECH is scheduled to hold a board meeting on March 30 to review its full-year results. In the first half of 2025, SCIENTECH's revenue from congenital heart disease occluder products reached RMB 161 million, accounting for 48.7% of its total revenue during the period, a year-on-year increase of 24.8%, making it the company's core revenue source.